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Abstract
Background Apremilast, an oral phosphodiesterase-4 inhibitor, has demonstrated efﬁcacy in patients with moderate
to severe psoriasis.
Objective To evaluate long-term efﬁcacy and safety of apremilast in biologic-naive patients with moderate to severe
plaque psoriasis and safety of switching from etanercept to apremilast in the phase 3b LIBERATE trial.
Methods Two hundred ﬁfty patients were randomized to placebo, apremilast 30 mg BID or etanercept 50 mg QW
through Week 16; thereafter, all patients continued or switched to apremilast through Week 104 (extension phase). Skin,
scalp and nail involvement at Weeks 16, 52 and 104 were assessed using the Psoriasis Area and Severity Index (PASI;
0–72), Scalp Physician Global Assessment (ScPGA; 0–5) and Nail Psoriasis Severity Index (NAPSI; 0–8); patient-reported
outcomes (PROs) were assessed using the Dermatology Life Quality Index (DLQI; 0–32) and pruritus visual analog scale
(VAS; 0–100 mm).
Results The apremilast-extension phase (Weeks 16–104) included 226 patients in the placebo/apremilast (n = 73),
apremilast/apremilast (n = 74) and etanercept/apremilast (n = 79) groups, and at Week 104, 50.7%, 45.9% and
51.9% of these patients, respectively, maintained ≥75% reduction from baseline in PASI score (based on last-obser-
vation-carried-forward analysis). Across treatment groups, ScPGA 0 (clear) or 1 (minimal) was achieved by 50.0%–
59.2% of patients; NAPSI mean change from baseline was 48.1% to 51.1%; DLQI score ≤5 was achieved by
66.0%–72.5% of patients; and pruritus VAS mean change from baseline was 24.4 to 32.3. AEs in ≥5% of patients
(diarrhoea, nausea, nasopharyngitis, upper respiratory tract infection and headache) did not increase with prolonged
apremilast exposure.
Conclusions Apremilast demonstrated signiﬁcant and sustained improvements in skin, scalp, nails and PROs (pruritus
and quality of life) over 104 weeks in patients with moderate to severe plaque psoriasis. Safety was consistent with the
known safety proﬁle of apremilast.
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Introduction
LIBERATE (NCT01690299), a global phase 3b study in biologic-
naive patients with moderate to severe plaque psoriasis, demon-
strated that significantly more patients receiving apremilast for
16 weeks achieved PASI-75 (≥75% reduction from baseline in
Psoriasis Area and Severity Index [PASI]) vs. placebo.1 A post
hoc analysis found no significant difference in response rates
among patients given apremilast vs. etanercept, an anti-tumour
necrosis factor-a biologic agent.1
This report describes efficacy and safety outcomes from the
LIBERATE apremilast-extension phase (Weeks 16–104) in
patients who continued apremilast treatment through 104 weeks,
including those who switched from etanercept or placebo.
Materials and methods
Patients and study design
Patient selection, study design and study methods have been
described in detail.1 Briefly, patients in the LIBERATE trial were
adults in the United States, Canada, Europe (Belgium, Czech
Republic, Estonia, Germany, Great Britain, Hungary, Latvia, the
Netherlands) or Australia with chronic, moderate to severe pla-
que psoriasis with inadequate response, inability to tolerate or
contraindication to treatment with ≥1 conventional systemic
agent, and who were biologic-naive. Eligible patients were ran-
domized (1 : 1 : 1) to double-blind treatment with apremilast
30 mg twice daily, etanercept subcutaneous injection 50 mg
once weekly, or placebo for 16 weeks. At Week 16, placebo and
etanercept patients were switched to apremilast (placebo, with-
out titration; etanercept, with 1-week titration); apremilast
patients continued apremilast treatment through Week 104.
Efﬁcacy and safety assessments
The primary efficacy end point, the proportion of patients who
achieved PASI-75 at Week 16, was previously reported.1 Efficacy
of continued apremilast treatment was evaluated at scheduled
visits over 104 weeks based on (i) skin symptoms, as assessed
using PASI improvement from baseline, achievement of PASI-75
response and achievement of response on the 5-point static
Physician Global Assessment (sPGA; response = score of 0
[clear] or 1 [almost clear]); (ii) change from baseline in pruritus,
as assessed using a 100-mm visual analog scale (VAS; 0 = no
pruritus, 100 = worst possible pruritus); (iii) scalp symptoms,
as assessed based on achievement of response on the 6-point
Scalp Physician Global Assessment (ScPGA; response = score of
0 [clear] or 1 [minimal]); (iv) nail symptoms, as assessed based
on improvement from baseline in Nail Psoriasis Severity Index
(NAPSI) score in the target nail and achievement of NAPSI-50†Employed by Celgene Corporation at the time of study conduct.
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(≥50% reduction from baseline in NAPSI score) among patients
with nail symptoms (i.e. NAPSI score ≥1); and (v) impact of
psoriasis on quality of life (QOL), as assessed by improvement
from baseline in Dermatology Life Quality Index (DLQI) total
score, achievement of DLQI total score ≤5 (minimal impair-
ment) and achievement of DLQI total score of 0 or 1. Safety was
assessed based on adverse events (AEs), vital signs, clinical labo-
ratory assessments and physical examinations.
Statistical analysis
Efficacy analyses were performed in the modified intent-to-treat
population (all randomized patients who received ≥1 dose of
study medication and had baseline PASI and ≥1 post-treatment
PASI assessments). Statistical analyses for between-group com-
parisons of efficacy assessments at Week 16 included Cochran–
Mantel–Haenszel tests for categorical variables and an analysis of
covariance model for continuous variables. Efficacy assessments
during the apremilast-extension phase were summarized using
descriptive statistics at visits after treatment initiation. Missing
values were imputed using last-observation-carried-forward
(LOCF) methodology. Responder analyses of DLQI total score
≤5 and DLQI score of 0 or 1 were performed using data from
completers without imputation. Safety was summarized using
descriptive statistics.1
Results
Patients
There were 233 patients who completed the placebo-controlled
phase among 250 randomized patients. There were 226 patients
who entered the apremilast-extension phase (placebo/apremilast,
n = 73; apremilast/apremilast, n = 74; etanercept/apremilast,
n = 79); 138 (60.8%) completed the Week 104 visit. The most
common reasons for withdrawal from the apremilast-extension
phase were lack of efficacy (n = 27, 11.9%), lost to follow-up
(n = 25, 11.0%) and withdrawal by patient (n = 24, 10.6%). Base-
line characteristics were balanced between groups.1 Mean psoriasis
duration was 18.2 years, and mean PASI score was 19.6.1
Efﬁcacy
At Week 16, significantly greater proportions of patients receiv-
ing apremilast vs. placebo achieved PASI-75 (39.8% vs. 11.9%,
P < 0.0001). In patients who continued or were switched
from placebo or etanercept to apremilast during the apremilast-
extension phase, PASI-75 response rate was maintained across
treatment groups at Week 52 (range, 52.7%–57.0%)1 and Week
104 (45.9%–51.9%; Table 1; Fig. 1) and was similar between
treatment groups. At Week 16, mean percentage improvement
in PASI score was significantly greater with apremilast compared
with placebo (P < 0.0001). Mean percentage improvement in
PASI score was maintained across treatment groups at Week 52
(range, 66.2%–75.1%)1 and continued through Week 104
(63.3%–70.1%; Table 1). Likewise, achievement of sPGA
response was significantly greater with apremilast vs. placebo at
Week 16 (21.7% vs. 3.6%, P = 0.0005)1; achievement was
24.3%–35.6% across treatment groups at Week 521 and 18.9%–
27.4% at Week 104 (Table 1).
Other signs and symptoms of psoriasis that were signifi-
cantly improved at Week 16 with apremilast vs. placebo
included pruritus, scalp involvement and nail involvement
(Fig. 2a and 2b). Improvements were maintained at Week 521
and Week 104 in patients who continued or were switched to
Table 1 Clinical response across efﬁcacy end points at Week 104 (LOCF)
Placebo/
Apremilast
Patient-Years = 95.6
Apremilast/
Apremilast
Patient-Years = 89.4
Etanercept/
Apremilast
Patient-Years = 102.3
PASI-75, n/m (%) 37/73 (50.7) 34/74 (45.9) 41/79 (51.9)
PASI percentage change from baseline, mean (SD) 63.3 (33.4) 63.7 (28.1) 70.1 (25.5)
sPGA 0 or 1, n/m (%) 20/73 (27.4) 14/74 (18.9) 21/79 (26.6)
ScPGA 0 or 1*, n/m (%) 25/50 (50.0) 29/49 (59.2) 30/53 (56.6)
NAPSI-50, n/m (%) 18/37 (48.6) 29/48 (60.4) 30/46 (65.2)
NAPSI percentage change from baseline*, mean (SD) 48.1 (49.6)
(n = 33)
48.2 (48.4)
(n = 48)
51.1 (72.2)
(n = 45)
Pruritus VAS change from baseline, mean (SD), mm 32.3 (33.4)
(n = 70)
26.6 (29.1)
(n = 71)
24.4 (31.2)
(n = 73)
DLQI ≤5, n† (%) 34/51 (66.7) 29/40 (72.5) 33/50 (66.0)
DLQI change from baseline, mean (SD) 5.6 (6.3)
(n = 69)
7.5 (7.0)
(n = 73)
5.2 (7.3)
(n = 73)
Data are from patients who entered the apremilast-extension phase and were treated in the phase; missing values were imputed using LOCF. *For ScPGA 0
or 1, data are from patients with ScPGA ≥3 (moderate or greater) at baseline and for NAPSI mean percentage change, among patients with NAPSI ≥1 at
baseline. †For DLQI ≤5, data are from patients with data at Week 104. n/m, number of responders/number of patients who entered and were treated in the
apremilast-extension phase. DLQI, Dermatology Life Quality Index; NAPSI, Nail Psoriasis Severity Index; NAPSI-50,≥50% reduction from baseline in NAPSI
score; PASI, Psoriasis Area and Severity Index; PASI-75,≥75% reduction from baseline in PASI score; sPGA, static Physician Global Assessment; ScPGA,
Scalp Physician Global Assessment.
© 2017 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd
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apremilast during the apremilast-extension phase. Mean
change from baseline in pruritus VAS score across treatment
groups was 31.7 to 35.9 mm at Week 521 and 24.4 to
32.3 mm at Week 104 (Table 1). At Weeks 52 and 104,
ScPGA response of 0 (clear) or 1 (minimal) was achieved by
52.0%–60.4%1 and 50.0%–59.2% of patients, respectively,
across treatment groups (Table 1; Fig. 2a). Mean percentage
change from baseline in NAPSI score ranged from 44.6% to
60.7% at Week 521 and 48.1% to 51.1% at Week 104
(Table 1; Fig. 2b). At Weeks 52 and 104, NAPSI-50 was
achieved by 50.0%–67.4% and 48.6%–65.2% of patients,
respectively, across treatment groups (Table 1). At baseline,
mean (SD) DLQI scores were 11.4 (6.3), 13.8 (6.6) and 12.5
(7.0) in the placebo, apremilast and etanercept groups, respec-
tively. At Week 16, there was a significant improvement with
apremilast vs. placebo in total DLQI score (mean change
from baseline, 8.3 vs. 3.8, P < 0.0001).1 At Weeks 52 and
104, mean change from baseline in DLQI score was 6.7 to
8.21 and 5.2 to 7.5 points, respectively (Table 1). At
Week 16, across treatment groups, 53.4%–65.0% of patients
achieved a DLQI score ≤5 (P = NS vs. placebo) (Fig. 2c). At
Weeks 52 and 104, DLQI ≤5 was achieved by 65.2%–74.6%
and 66.0%–72.5% of patients, respectively, across treatment
groups (Table 1; Fig. 2c). Among patients remaining in the
study at Week 104, 19/51 (37.3%), 12/40 (30.0%) and 13/50
(26.0%) achieved a DLQI score of 0 or 1 at Week 104 in the
placebo/apremilast, apremilast/apremilast and etanercept/
apremilast groups, respectively.
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Safety
During the apremilast-extension phase, most AEs were mild or
moderate in severity, and incidence of serious adverse events
(SAEs) was similar across groups (Table 2). Discontinuation
rates due to AEs were generally low across groups during the
apremilast-extension phase. No deaths occurred during the
study. For AEs that occurred in ≥5% of patients during the pla-
cebo-controlled phase (diarrhoea, nausea, upper respiratory
tract infection, nasopharyngitis, headache and tension head-
ache1), no increase in incidence was observed among patients in
the apremilast/apremilast group with long-term exposure
(Table 2). No psychiatric AEs occurred in ≥5% of patients dur-
ing the placebo-controlled phase or with long-term exposure in
patients who continued or were switched to apremilast.1 During
the apremilast-extension phase, four patients in the apremilast/
apremilast group reported five psychiatric AEs (n = 1 [1.4%]
each AE): anxiety, depression, insomnia, depressed mood and
stress. Among placebo/apremilast or etanercept/apremilast
patients, one in each group (1.4%, 1.3%, respectively) experi-
enced an AE of depression, anxiety and insomnia. Among pla-
cebo/apremilast patients, psychotic disorder and suicidal
ideation were experienced by one (1.4%) patient each; among
etanercept/apremilast patients, two patients (2.5%) experienced
altered mood. In patients reporting AEs of rebound psoriasis in
the etanercept/apremilast group, the majority of events (five of
seven) involved loss of PASI response after treatment was dis-
continued or completed, and no patients experienced worsening
of PASI score ≥125% of baseline.
All cases of diarrhoea and nausea occurring in the apremilast-
extension phase were mild or moderate in severity and generally
resolved within 1 month. Of note, patients in the placebo/
apremilast group had no dose titration with apremilast at Week
16, which likely explains the higher incidence of diarrhoea in the
placebo/apremilast group (17.8%) compared with incidence of
diarrhoea with apremilast during the placebo-controlled phase
(10.8%).1 Marked laboratory abnormalities were infrequent and
transient; incidence remained low across groups with continued
apremilast treatment through 104 weeks. At Week 104, mean
percentage change from baseline in bodyweight was 1.1% (pla-
cebo/apremilast), 0.21% (apremilast/apremilast) and 1.9%
(etanercept/apremilast).
Discussion
Apremilast treatment in biologic-naive patients with moderate
to severe psoriasis was effective and safe for up to 104 weeks,
with improvements in skin, scalp, nails, pruritus and QOL.
Efficacy and safety were maintained in patients who switched
from etanercept to apremilast and remained in the study at
Week 104. Patients also experienced minimal impact of psori-
asis on QOL, with ≥66% of patients achieving DLQI ≤5 at
Table 2 Summary of adverse events during the apremilast-extension phase (Weeks 16–104)
Placebo/Apremilast*
n = 73
Patient-years = 95.6
Apremilast/Apremilast
n = 74
Patient-years = 89.4
Etanercept/Apremilast†
n = 79
Patient-years = 102.3
Patients, n (%)
≥1 AE 45 (61.6) 49 (66.2) 54 (68.4)
≥1 Severe AE 4 (5.5) 4 (5.4) 7 (8.9)
≥1 SAE 5 (6.8) 3 (4.1) 4 (5.1)
AE leading to withdrawal 3 (4.1) 4 (5.4) 2 (2.5)
AE leading to death 0 (0.0) 0 (0.0) 0 (0.0)
AEs occurring in ≥5% of patients in any treatment group, n (%)‡
Diarrhoea 13 (17.8) 4 (5.4) 6 (7.6)
Nausea 5 (6.8) 3 (4.1) 5 (6.3)
URTI 5 (6.8) 5 (6.8) 1 (1.3)
Bronchitis 1 (1.4) 4 (5.4) 1 (1.3)
Nasopharyngitis 4 (5.5) 2 (2.7) 5 (6.3)
Headache 5 (6.8) 2 (2.7) 3 (3.8)
Sinusitis 0 (0.0) 1 (1.4) 5 (6.3)
Pain in extremity 1 (1.4) 3 (4.1) 4 (5.1)
Arthralgia 4 (5.5) 4 (5.4) 3 (3.8)
Rebound psoriasis 1 (1.4) 2 (2.7) 7 (8.9)
Psoriasis 2 (2.7) 4 (5.4) 0 (0.0)
Data are from patients who entered the apremilast-extension phase and were treated in the phase.
*No dose titration for apremilast. †Dose titration for apremilast. ‡Each patient is counted once for each applicable category. AE, adverse event; SAE, serious
adverse event; URTI, upper respiratory tract infection.
© 2017 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd
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Week 104. Improved QOL may help motivate patients to
maintain treatment over time, which may lead to better dis-
ease control. The safety profile of apremilast during the
apremilast-extension phase was consistent with the ESTEEM
and PALACE trials.2–7
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